View in EDS

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.

Saved in:
Bibliographic Details
Title: Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.
Authors: Motzer RJ; Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. motzerr@mskcc.org., Robbins PB; Translational Oncology, Pfizer, San Diego, CA, USA., Powles T; Department of Genitourinary Oncology, Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomew's Hospital, London, UK., Albiges L; Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France., Haanen JB; Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Larkin J; Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, London, UK., Mu XJ; Computational Biology, Pfizer, San Diego, CA, USA., Ching KA; Computational Biology, Pfizer, San Diego, CA, USA., Uemura M; Graduate School of Medicine, Osaka University Hospital, Osaka, Japan., Pal SK; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Alekseev B; Deputy Director for Science, Moscow Scientific Research Oncology Institute, Moscow, Russian Federation., Gravis G; Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France., Campbell MT; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Penkov K; Private Medical Institution, Euromedservice, St. Petersburg, Russian Federation., Lee JL; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea., Hariharan S; Oncology, Pfizer, New York, NY, USA., Wang X; Computational Biology, Pfizer, San Diego, CA, USA.; Lyell Immunopharma, South San Francisco, CA, USA., Zhang W; Biostatistics, Pfizer, Cambridge, MA, USA.; Jounce Therapeutics, Cambridge, MA, USA., Wang J; Biostatistics, Pfizer, Cambridge, MA, USA., Chudnovsky A; Oncology, Pfizer, Cambridge, MA, USA.; Ipsen, Cambridge, MA, USA., di Pietro A; Immuno-Oncology, Pfizer, Milan, Italy., Donahue AC; Translational Oncology, Pfizer, La Jolla, CA, USA., Choueiri TK; Department of Medical Oncology, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA. toni_choueiri@dfci.harvard.edu.
Source: Nature medicine [Nat Med] 2020 Nov; Vol. 26 (11), pp. 1733-1741. Date of Electronic Publication: 2020 Sep 07.
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 32895571
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Motzer+RJ%22">Motzer RJ</searchLink>; Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. motzerr@mskcc.org.<br /><searchLink fieldCode="AU" term="%22Robbins+PB%22">Robbins PB</searchLink>; Translational Oncology, Pfizer, San Diego, CA, USA.<br /><searchLink fieldCode="AU" term="%22Powles+T%22">Powles T</searchLink>; Department of Genitourinary Oncology, Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomew's Hospital, London, UK.<br /><searchLink fieldCode="AU" term="%22Albiges+L%22">Albiges L</searchLink>; Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.<br /><searchLink fieldCode="AU" term="%22Haanen+JB%22">Haanen JB</searchLink>; Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Larkin+J%22">Larkin J</searchLink>; Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, London, UK.<br /><searchLink fieldCode="AU" term="%22Mu+XJ%22">Mu XJ</searchLink>; Computational Biology, Pfizer, San Diego, CA, USA.<br /><searchLink fieldCode="AU" term="%22Ching+KA%22">Ching KA</searchLink>; Computational Biology, Pfizer, San Diego, CA, USA.<br /><searchLink fieldCode="AU" term="%22Uemura+M%22">Uemura M</searchLink>; Graduate School of Medicine, Osaka University Hospital, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Pal+SK%22">Pal SK</searchLink>; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.<br /><searchLink fieldCode="AU" term="%22Alekseev+B%22">Alekseev B</searchLink>; Deputy Director for Science, Moscow Scientific Research Oncology Institute, Moscow, Russian Federation.<br /><searchLink fieldCode="AU" term="%22Gravis+G%22">Gravis G</searchLink>; Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France.<br /><searchLink fieldCode="AU" term="%22Campbell+MT%22">Campbell MT</searchLink>; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Penkov+K%22">Penkov K</searchLink>; Private Medical Institution, Euromedservice, St. Petersburg, Russian Federation.<br /><searchLink fieldCode="AU" term="%22Lee+JL%22">Lee JL</searchLink>; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Hariharan+S%22">Hariharan S</searchLink>; Oncology, Pfizer, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Wang+X%22">Wang X</searchLink>; Computational Biology, Pfizer, San Diego, CA, USA.; Lyell Immunopharma, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Zhang+W%22">Zhang W</searchLink>; Biostatistics, Pfizer, Cambridge, MA, USA.; Jounce Therapeutics, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Wang+J%22">Wang J</searchLink>; Biostatistics, Pfizer, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Chudnovsky+A%22">Chudnovsky A</searchLink>; Oncology, Pfizer, Cambridge, MA, USA.; Ipsen, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22di+Pietro+A%22">di Pietro A</searchLink>; Immuno-Oncology, Pfizer, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Donahue+AC%22">Donahue AC</searchLink>; Translational Oncology, Pfizer, La Jolla, CA, USA.<br /><searchLink fieldCode="AU" term="%22Choueiri+TK%22">Choueiri TK</searchLink>; Department of Medical Oncology, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA. toni_choueiri@dfci.harvard.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229502015%22">Nature medicine</searchLink> [Nat Med] 2020 Nov; Vol. 26 (11), pp. 1733-1741. <i>Date of Electronic Publication: </i>2020 Sep 07.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Company%22">Nature Publishing Company </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502015 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1546-170X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210788956%22">10788956 </searchLink><i>NLM ISO Abbreviation: </i>Nat Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32895571
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41591-020-1044-8
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1733
    Titles:
      – TitleFull: Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Motzer RJ
      – PersonEntity:
          Name:
            NameFull: Robbins PB
      – PersonEntity:
          Name:
            NameFull: Powles T
      – PersonEntity:
          Name:
            NameFull: Albiges L
      – PersonEntity:
          Name:
            NameFull: Haanen JB
      – PersonEntity:
          Name:
            NameFull: Larkin J
      – PersonEntity:
          Name:
            NameFull: Mu XJ
      – PersonEntity:
          Name:
            NameFull: Ching KA
      – PersonEntity:
          Name:
            NameFull: Uemura M
      – PersonEntity:
          Name:
            NameFull: Pal SK
      – PersonEntity:
          Name:
            NameFull: Alekseev B
      – PersonEntity:
          Name:
            NameFull: Gravis G
      – PersonEntity:
          Name:
            NameFull: Campbell MT
      – PersonEntity:
          Name:
            NameFull: Penkov K
      – PersonEntity:
          Name:
            NameFull: Lee JL
      – PersonEntity:
          Name:
            NameFull: Hariharan S
      – PersonEntity:
          Name:
            NameFull: Wang X
      – PersonEntity:
          Name:
            NameFull: Zhang W
      – PersonEntity:
          Name:
            NameFull: Wang J
      – PersonEntity:
          Name:
            NameFull: Chudnovsky A
      – PersonEntity:
          Name:
            NameFull: di Pietro A
      – PersonEntity:
          Name:
            NameFull: Donahue AC
      – PersonEntity:
          Name:
            NameFull: Choueiri TK
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: 2020 Nov
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-electronic
              Value: 1546-170X
          Numbering:
            – Type: volume
              Value: 26
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: Nature medicine
              Type: main
ResultId 1